ORS whistleblower calls for joint-regulatory protocol to curb misleading brand sales

Delivering a special address at the 2nd edition of ETHealthworld NutriWell Conclave, Dr. Shivranjani Santosh said, loopholes in trademark rules give companies space to exploit drugs as trademarks. However, a “joint regulatory framework” involving apex regulators CDSCO and FSSAI could help extend the required scrutiny to curb their market entry and prevent mislabelling.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/1bqXo6a
via